Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Industry

Public Meeting on Narcolepsy Patient-Focused Drug Development

On September 24, 2013, FDA conducted a public meeting on Patient-Focused Drug Development for narcolepsy. FDA is interested in obtaining patient input on the impact of narcolepsy on daily life and the available therapies for narcolepsy


September 24, 2013


1 p.m. to 5 p.m.


FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A
Silver Spring, MD 20993
(Information about arrival to FDA's White Oak campus)


To register for this meeting, visit:
Registration closed on September 13, 2013.

Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. Visit the following website to provide electronic or written comments:!submitComment;D=FDA-2013-N-0815-0001.

Alternatively, you can submit comments through fax or mail. Fax comments to the Division of Dockets Management at 301-827-6870, or mail comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should include the docket number FDA-2013-N-0815.


Page Last Updated: 04/19/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English